Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M95,727Revenue $M7,670Net Margin (%)26.1Z-Score7.3
Enterprise Value $M95,703EPS $2.4Operating Margin %32.8F-Score7
P/E(ttm))62.6Cash Flow Per Share $4.4Pre-tax Margin (%)30.3Higher ROA y-yN
Price/Book16.610-y EBITDA Growth Rate %0Quick Ratio6.1Cash flow > EarningsY
Price/Sales13.05-y EBITDA Growth Rate %0Current Ratio6.3Lower Leverage y-yN
Price/Cash Flow17.9y-y EBITDA Growth Rate %11.0ROA % (ttm)16.7Higher Current Ratio y-yY
Dividend Yield %0Insider Buy (3m)0ROE % (ttm)45.1Less Shares Outstanding y-yY
Payout Ratio %0Shares Outstanding M799ROI % (ttm)17.8Gross Margin Increase y-yY

Gurus Latest Trades with CELG

Number of guru portfolios checked: 85. (List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)
TickerGuruDate Action
Impactdown Price Range
(Average)*
Current Price Change from Average Comment Current Shares
CELGJoel Greenblatt 2014-12-31 Buy 0.01%$86.38 - $118.68
($105.73)
$ 119.5713%New holding, 10259 sh.10,259
CELGRonald Muhlenkamp 2014-12-31 Reduce-1.03%$86.38 - $118.68
($105.53)
$ 119.5713%Reduce -41.31%86,240
CELGJohn Hussman 2014-12-31 Sold Out -0.2%$86.38 - $118.68
($105.53)
$ 119.5713%Sold Out0
CELGJohn Hussman 2014-09-30 Buy 0.2%$83.13 - $96.21
($90.29)
$ 119.5732%New holding, 25000 sh.25,000
CELGKen Fisher 2014-09-30 Add0.02%$83.13 - $96.21
($90.29)
$ 119.5732%Add 77.12%232,137
CELGGeorge Soros 2014-09-30 Sold Out -0.45%$83.13 - $96.21
($90.29)
$ 119.5732%Sold Out0
CELGJoel Greenblatt 2014-09-30 Sold Out -0.07%$83.13 - $96.21
($90.29)
$ 119.5732%Sold Out0
CELGGeorge Soros 2014-06-30 Buy 0.45%$68.45 - $86.8
($75.89)
$ 119.5758%New holding, 688000 sh.688,000
CELGJoel Greenblatt 2014-06-30 Buy 0.07%$68.45 - $86.8
($75.89)
$ 119.5758%New holding, 63980 sh.63,980
CELGKen Fisher 2014-06-30 Add0.01%$68.45 - $86.8
($75.89)
$ 119.5758%Add 75.59%131,064
CELGRonald Muhlenkamp 2014-06-30 Reduce-1.91%$68.45 - $86.8
($75.89)
$ 119.5758%Reduce -51.74%144,140
CELGRay Dalio 2014-06-30 Sold Out -0.08%$68.45 - $86.8
($75.89)
$ 119.5758%Sold Out0
CELGJohn Burbank 2014-06-30 Sold Out -0.01%$68.45 - $86.8
($75.89)
$ 119.5758%Sold Out0
CELGRay Dalio 2014-03-31 Add0.07%$69.65 - $85.97
($79.51)
$ 119.5750%Add 962.69%142,400
CELGJohn Burbank 2014-03-31 Buy 0.01%$69.65 - $85.97
($79.51)
$ 119.5750%New holding, 1670 sh.3,340
CELGKen Fisher 2014-03-31 Add0.01%$69.65 - $85.97
($79.48)
$ 119.5750%Add 1591.8%74,642
CELGJohn Keeley 2014-03-31 Sold Out $69.65 - $85.97
($79.51)
$ 119.5750%Sold Out0
CELGRonald Muhlenkamp 2013-12-31 Add0.12%$72.25 - $85.39
($79.05)
$ 119.5751%Add 2.87%294,850
CELGRay Dalio 2013-12-31 Buy 0.01%$72.25 - $85.39
($79.05)
$ 119.5751%New holding, 6700 sh.13,400
CELGKen Fisher 2013-09-30 Reduce$60.13 - $77.31
($70.14)
$ 119.5770%Reduce -44.85%4,980
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

CELG is held by these Gurus:

Ticker Guru Name Portfolio Date* Current Shares % of Shares Outstanding % of Total Assets Managed Change from Last Holdings Holding History
CELG Joel Greenblatt 2014-12-3110,25900.01New Buy
CELG Ken Fisher 2014-12-31227,3310.030.05-2.07%
CELG Mario Gabelli 2014-12-3124,96000.02-3.11%
CELG Ronald Muhlenkamp 2014-12-3186,2400.011.9-41.31%
CELG John Hussman 2014-12-31000Sold Out
Premium Most recent portfolio changes are included for Premium Members only!


CELG: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
KAPLAN GILLADirector 2015-02-26Sell15,000$122.89-2.1view
CASEY MICHAEL DDirector 2015-02-25Sell15,000$123.19-2.34view
KARSEN PERRY Asee remarks 2015-02-11Sell27,896$120.120.16view
Alles Mark JSee Remarks 2015-02-06Sell117,099$120.68-0.31view
STEIN LAWRENCE VSee Remarks 2015-01-15Sell26,666$120.010.25view
KAPLAN GILLADirector 2015-01-02Sell45,536$113.476.03view
Daniel Thomas Osee remarks 2014-12-15Sell30,000$115.064.56view
KAPLAN GILLADirector 2014-12-08Sell15,000$118.21.79view
Daniel Thomas Osee remarks 2014-11-24Sell33,818$110.279.1view
KARSEN PERRY Asee remarks 2014-11-12Sell39,420$107.2312.2view

Press Releases about CELG :

    Quarterly/Annual Reports about CELG:

    News about CELG:

    Articles On GuruFocus.com
    February Pick Of Biotech Stocks Feb 17 2015 
    Celleration Acquisition Just the Start of Alliqua’s M&A Strategy Feb 04 2015 
    J.P. Morgan Chimes In With Ratings On BioTech Stocks Jan 06 2015 
    UPDATE: Bionor Pharma Announces That the Combination of Vacc-4x + Revlimid(R) Is Well Tolerated and Nov 18 2014 
    Bionor Pharma Announces That the Combination of Vacc-4x + Revlimid(R) Is Safe and Increases CD4 Coun Nov 17 2014 
    Three Attractively Priced Small Cap Biotech Stocks Nov 05 2014 
    Weekly 52-Week Highs Highlight: ALL, SRE, CLX, CELG Oct 05 2014 
    Ken Fisher's Top Increases of the First Quarter Apr 22 2014 
    David Winters' 2013 Letter to Wintergreen Fund Shareholders Mar 05 2014 
    You Can No Longer Ignore Biotech Feb 07 2014 


    More From Other Websites
    Best bets for Nasdaq 5K Mar 02 2015
    Midday Glance: Biotechnology companies Mar 02 2015
    ABRAXANE® Approved by European Commission for First-Line Treatment of Patients with Non-Small Cell... Mar 02 2015
    Analysts: The single best stock to own today Mar 01 2015
    Stock Market Video Analysis for Week Ending 2/27/15 Feb 28 2015
    CELGENE CORP /DE/ Financials Feb 27 2015
    Early Glance: Biotechnology companies Feb 27 2015
    The Zacks Analyst Blog Highlights: Pharmacyclics, Celgene, Amgen and Regeneron - Press Releases Feb 27 2015
    Multiple Myeloma: A Growing Market For Treatment Feb 26 2015
    The single best stock to own today Feb 26 2015
    Biotech Stock Roundup: Pharmacyclics Up on Buyout Rumors, Celgene Drug Label Expanded - Analyst Blog Feb 26 2015
    Medivation Tops Q4 Views On Strong Xtandi Results Feb 26 2015
    Short Sellers Increase Bets Against Biotech as Shares Continue to Rise Feb 26 2015
    Celgene Encourages Psoriatic Arthritis Patients to “pSAY YES!” a Different Approach to Disease... Feb 25 2015
    Is A Renaissance In Surging Biotechs Underway? Feb 25 2015
    Psoriatic Arthritis Patients "pSAY YES!" to a Different Approach to Disease Management Feb 25 2015
    Brain-Altering Devices May Supplant Drugs -- And Pharma Is OK With That Feb 24 2015
    In The Book Of Life, A Second Map Is Established Feb 24 2015
    United Therapeutics Blood Pressure Drug Lifts Q4 Feb 24 2015
    ABRAXANE® Now Reimbursed in Italy as a First-Line Treatment of Adult Patients with Metastatic... Feb 24 2015

    Add Notes, Comments

    If you want to ask a question, or report a bug, please create a support ticket.

    User Comments

    No comment yet
    Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
    GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
    Free 7-day Trial
    FEEDBACK